<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686582</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-023</org_study_id>
    <secondary_id>EudraCT-No.2007-006297-28</secondary_id>
    <secondary_id>DMID 08-0018</secondary_id>
    <nct_id>NCT00686582</nct_id>
  </id_info>
  <brief_title>An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees</brief_title>
  <official_title>An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was preformed to evaluate the persistence of antibodies following vaccination with
      MVA-BN and to assess the immunological memory response induced by a booster vaccination with
      MVA-BN in subjects two years after their participation in trial POX-MVA-005 (NCT00316524) in
      which they had received one or two doses of MVA-BN.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual Peak Booster Rate by ELISA (Percentage of Participants)</measure>
    <time_frame>within 4 weeks</time_frame>
    <description>Booster rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Individual Peak booster rate is based on the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Percentages based on number of subjects with data available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Booster Rate by ELISA (Percentage of Participants)</measure>
    <time_frame>within 26 weeks</time_frame>
    <description>Booster rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT</measure>
    <time_frame>within 26 weeks</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Rate by PRNT (Percentage of Participants)</measure>
    <time_frame>within 26 weeks</time_frame>
    <description>Booster rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects.
Individual Peak booster rate is based on the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4).
Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT GMT</measure>
    <time_frame>within 26 weeks</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Individual peak is defined as the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation PRNT vs ELISA Titers</measure>
    <time_frame>within 26 weeks</time_frame>
    <description>Pearson Correlation Coefficient between the log10 transformed PRNT titers and the log10 transformed ELISA titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Serious Adverse Events</measure>
    <time_frame>within 26 weeks</time_frame>
    <description>Number of participants with Serious Adverse Events (SAEs) probably, possibly or definitely related to the trial vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Non-serious Adverse Events</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Number of participants with any, grade &gt;=3, and related non-serious unsolicited adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Grade &gt;= 3 Unsolicited Adverse Events</measure>
    <time_frame>within 29 days after vaccination</time_frame>
    <description>Number of participants with Grade &gt;=3 Unsolicited Adverse Event probably, possibly, or definitely related to the study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Events</measure>
    <time_frame>within 8 days after vaccination</time_frame>
    <description>Number of participants with and intensity of solicited local AEs (pain, erythema, swelling, induration, and pruritis). Percentages based on subjects with a completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited General Adverse Events</measure>
    <time_frame>within 8 days after vaccination</time_frame>
    <description>Number of participants with solicited general AEs (body temperature increased, headache, myalgia, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with a completed diary card.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Initially Vaccinia Naive, 2 dose primed, 1 booster dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initially Vaccinia Naive, 1 dose primed, 1 booster dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccinia Experienced, boosted, blood draw only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group 4 Vaccinia Experienced
1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE</intervention_name>
    <description>1x 10E8_TCID50</description>
    <arm_group_label>Initially Vaccinia Naive, 2 dose primed, 1 booster dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE</intervention_name>
    <description>1x 10E8_TCID50</description>
    <arm_group_label>Initially Vaccinia Naive, 1 dose primed, 1 booster dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw Only</intervention_name>
    <arm_group_label>Vaccinia Experienced, boosted, blood draw only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Groups 1 and 2 (first consenting 75 subjects in each group to be vaccinated)

          -  Male and female subjects having participated in Group 1 or 2 of the study POX-MVA-005
             who completed the trial according to protocol.

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and a negative urine or serum pregnancy test within 24 hours prior to vaccination.

          -  Women of childbearing potential must have used an acceptable method of contraception
             for 30 days prior to the vaccination, must agree to use an acceptable method of
             contraception during the study, and must not become pregnant for at least 28 days
             after the vaccination. A woman is considered of childbearing potential unless
             post-menopausal or surgically sterilized. (Acceptable contraception methods are
             restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices
             or licensed hormonal products.)

          -  Read, signed and dated informed consent document after being advised of the risks and
             benefits of the study in a language understood by the subject signed, and prior to
             performance of any study specific procedure.

          -  Troponin I within normal institutional limits.

          -  White blood cells ≥ 2,500/mm3 and &lt;= 11,000/mm3.

          -  Absolute neutrophil count within normal limits.

          -  Negative urine glucose by dipstick or urinalysis.

          -  Hemoglobin within the laboratory reference ranges (unless the investigator considers
             the deviation to be not clinically significant).

          -  Platelets 100 - 440/nL.

          -  Adequate renal function defined as:

               1. Serum creatinine without clinically significant findings.

               2. Urine protein &lt;= 30 mg/dL or none or trace proteinuria (by urinalysis or dip
                  stick).

          -  Adequate hepatic function defined as:

               1. Total bilirubin &lt;= 1.5 x upper limit of normal (ULN) in the absence of other
                  evidence of significant liver disease (healthy subjects without clinical disease;
                  Morbus Meulengracht can be included).

               2. AST (SGOT), ALT (SGPT), alkaline phosphatase without clinically significant
                  findings.

          -  Electrocardiogram (ECG) without clinically relevant abnormal findings (e.g. any kind
             of atrioventricular or intraventricular conditions or blocks such as complete left or
             right bundle branch block, AV node block, QTc or PR prolongation, premature atrial
             contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two
             premature ventricular contractions (PVC) in a row, ST elevation consistent with
             ischemia).

        Group 4 (all subjects) and Groups 1 and 2 (subjects N &gt; 75): blood draw only

          -  Male and female subjects having participated in the study POX-MVA-005 who completed
             the trial according to protocol.

          -  Read, signed and dated informed consent document after being advised of the risks and
             benefits of the blood draw in a language understood by the subject signed, and prior
             to performance of the blood draw.

        Exclusion Criteria:

        Groups 1 and 2 (first consenting 75 subjects in each group to be vaccinated)

          -  Participation in another study with a smallpox vaccine after the POX-MVA-005 study.

          -  Pregnant or breast-feeding women.

          -  Uncontrolled serious infection i.e. not responding to antimicrobial therapy.

          -  History of any serious medical condition, which in the opinion of the investigator
             would compromise the safety of the subject.

          -  History of or active autoimmune disease. Persons with vitiligo or thyroid disease
             taking thyroid replacement are not excluded.

          -  Known or suspected impairment of immunologic function including, but not limited to,
             clinically significant liver disease; diabetes mellitus; moderate to severe kidney
             impairment.

          -  History of malignancy, other than squamous cell or basal cell skin cancer, unless
             there has been surgical excision that is considered to have achieved cure. Subjects
             with history of skin cancer must not be vaccinated at the previous site of cancer.

          -  History or clinical manifestation of clinically significant and severe hematological,
             renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal
             disorders.

          -  Clinically significant mental disorder not adequately controlled by medical treatment.

          -  Any condition which might interfere with study objectives or would limit the subject's
             ability to complete the study or to be compliant in the opinion of the investigator.

          -  History of coronary heart disease, myocardial infarction, angina, congestive heart
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood
             pressure, or any other heart condition under the care of a doctor.

          -  History of an immediate family member (father, mother, brother, or sister) who died
             due to ischemic heart disease before age 50 years.

          -  Twenty percent or greater risk of developing a myocardial infarction or coronary death
             within the next 10 years using the National Cholesterol Education Program's risk
             assessment tool. (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof).

          -  History of intravenous drug abuse.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine, e.g. tris (hydroxymethyl)-amino methane, chicken embryo fibroblast
             proteins, aminoglycosides (gentamycin).

          -  History of any anaphylactic shock or severe allergic reaction requiring immediate
             treatment.

          -  Having received any vaccinations or planned vaccinations with a live vaccine within 30
             days prior or after study vaccination.

          -  Having received any vaccinations or planned vaccinations with a killed vaccine within
             14 days prior or after study vaccination.

          -  Chronic administration (defined as more than 14 days) of &gt; 5 mg prednisone (or
             equivalent) per day or any other immune-modifying drugs during a period starting from
             three months prior to administration of the vaccine and ending at study conclusion
             (Visit 4).

          -  Post organ transplant subjects whether or not receiving chronic immunosuppressive
             therapy.

          -  Administration or planned administration of immunoglobulins and/or any blood products
             during a period starting from 3 months prior to administration of the vaccine and
             ending at study conclusion.

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine within 30 days preceding administration of the study vaccine, or planned
             administration of such a drug during the study period.

        Group 4 (all subjects) and Groups 1 and 2 (subjects N &gt; 75): blood draw only

          -  Participation in another study with a smallpox vaccine after the POX-MVA-005 study.

          -  Any condition which might interfere with a blood draw.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harrison Clinical Research Deutschland GmbH</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>December 19, 2018</results_first_submitted>
  <results_first_submitted_qc>February 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2019</results_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
          <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
        </group>
        <group group_id="P2">
          <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
          <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
        </group>
        <group group_id="P3">
          <title>Vaccinia Experienced, Boosted, Blood Draw Only</title>
          <description>Group 4 Vaccinia Experienced
1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Booster Vaccination</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Persistence Set i.e. subjects previously vaccinated in study POX-MVA-005 with a blood draw at the screening visit of study POX-MVA-023</population>
      <group_list>
        <group group_id="B1">
          <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
          <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
        </group>
        <group group_id="B2">
          <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
          <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
        </group>
        <group group_id="B3">
          <title>Vaccinia Experienced, Boosted, Blood Draw Only</title>
          <description>Group 4 Vaccinia Experienced
1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="121"/>
            <count group_id="B4" value="304"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="5.8"/>
                    <measurement group_id="B2" value="27.7" spread="4.5"/>
                    <measurement group_id="B3" value="44.9" spread="6.6"/>
                    <measurement group_id="B4" value="34.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ELISA Long-Term Persistence</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA) at the Screening Visit (2 years after one or two doses of MVA-BN in POX-MVA-005) are considered long-term immunogenicity outcomes from previous study. Titers below the detection limit are included with a value of '1'.
Total Column: Pooled data is of limited relevance due to different precondition (naive vs experienced) / treatment (2 doses vs 1 dose of MVA-BN) in POX-MVA-005.</description>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.33" lower_limit="1" upper_limit="1877"/>
                    <measurement group_id="B2" value="6.20" lower_limit="1" upper_limit="262"/>
                    <measurement group_id="B3" value="134.65" lower_limit="1" upper_limit="1103"/>
                    <measurement group_id="B4" value="31.52" lower_limit="1" upper_limit="1877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PRNT Long-Term Persistence</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT) at the Screening Visit (2 years after one or two doses of MVA-BN in POX-MVA-005) are considered long-term immunogenicity outcomes from previous study. Titers below the detection limit are included with a value of '1'.
Total Column: Pooled data is of limited relevance due to different precondition (naive vs experienced) / treatment (2 doses vs 1 dose of MVA-BN) in POX-MVA-005.</description>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.26" lower_limit="1" upper_limit="226"/>
                    <measurement group_id="B2" value="1.05" lower_limit="1" upper_limit="67"/>
                    <measurement group_id="B3" value="10.28" lower_limit="1" upper_limit="4382"/>
                    <measurement group_id="B4" value="2.75" lower_limit="1" upper_limit="4382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Individual Peak Booster Rate by ELISA (Percentage of Participants)</title>
        <description>Booster rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Individual Peak booster rate is based on the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Percentages based on number of subjects with data available.</description>
        <time_frame>within 4 weeks</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Peak Booster Rate by ELISA (Percentage of Participants)</title>
          <description>Booster rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Individual Peak booster rate is based on the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Rate by ELISA (Percentage of Participants)</title>
        <description>Booster rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>within 26 weeks</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Rate by ELISA (Percentage of Participants)</title>
          <description>Booster rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="93.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="92.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT</title>
        <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>within 26 weeks</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Titers below the detection limit are included with a value of '1'.</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.23" lower_limit="15.20" upper_limit="38.62"/>
                    <measurement group_id="O2" value="5.89" lower_limit="3.63" upper_limit="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="737.93" lower_limit="597.37" upper_limit="911.58"/>
                    <measurement group_id="O2" value="490.33" lower_limit="368.48" upper_limit="652.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1688.20" lower_limit="1381.55" upper_limit="2062.91"/>
                    <measurement group_id="O2" value="1608.89" lower_limit="1285.90" upper_limit="2013.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1255.21" lower_limit="1029.02" upper_limit="1531.13"/>
                    <measurement group_id="O2" value="1210.59" lower_limit="974.01" upper_limit="1504.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1821.57" lower_limit="1496.13" upper_limit="2217.80"/>
                    <measurement group_id="O2" value="1723.74" lower_limit="1376.87" upper_limit="2158.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.78" lower_limit="381.16" upper_limit="559.46"/>
                    <measurement group_id="O2" value="382.91" lower_limit="301.66" upper_limit="486.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Booster Rate by PRNT (Percentage of Participants)</title>
        <description>Booster rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects.
Individual Peak booster rate is based on the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4).
Percentages based on number of subjects with data available.</description>
        <time_frame>within 26 weeks</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Booster Rate by PRNT (Percentage of Participants)</title>
          <description>Booster rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT) is defined as the percentage of subjects with an appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects.
Individual Peak booster rate is based on the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4).
Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="83.4" upper_limit="97.0"/>
                    <measurement group_id="O2" value="85.7" lower_limit="75.9" upper_limit="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="92.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.1" lower_limit="89.0" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" lower_limit="86.7" upper_limit="98.5"/>
                    <measurement group_id="O2" value="90.9" lower_limit="82.2" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual peak</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="92.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="93.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="79.0" upper_limit="95.0"/>
                    <measurement group_id="O2" value="76.6" lower_limit="65.6" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT GMT</title>
        <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Individual peak is defined as the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>within 26 weeks</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT GMT</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Individual peak is defined as the maximum post-Baseline antibody titer within 4 weeks (measurements at Weeks 1, 2, and 4). Titers below the detection limit are included with a value of '1'.</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.99" upper_limit="1.52"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.95" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.61" lower_limit="37.05" upper_limit="77.59"/>
                    <measurement group_id="O2" value="28.58" lower_limit="18.56" upper_limit="43.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.26" lower_limit="89.51" upper_limit="175.27"/>
                    <measurement group_id="O2" value="80.69" lower_limit="54.37" upper_limit="119.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.26" lower_limit="43.19" upper_limit="95.61"/>
                    <measurement group_id="O2" value="48.96" lower_limit="31.72" upper_limit="75.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Individual Peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.97" lower_limit="124.21" upper_limit="221.77"/>
                    <measurement group_id="O2" value="116.79" lower_limit="82.42" upper_limit="165.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.29" lower_limit="32.40" upper_limit="74.98"/>
                    <measurement group_id="O2" value="25.62" lower_limit="15.84" upper_limit="41.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation PRNT vs ELISA Titers</title>
        <description>Pearson Correlation Coefficient between the log10 transformed PRNT titers and the log10 transformed ELISA titers</description>
        <time_frame>within 26 weeks</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation PRNT vs ELISA Titers</title>
          <description>Pearson Correlation Coefficient between the log10 transformed PRNT titers and the log10 transformed ELISA titers</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Thus, Group 4 is not included.</population>
          <units>Pearson correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.591"/>
                    <measurement group_id="O2" value="0.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.491"/>
                    <measurement group_id="O2" value="0.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.476"/>
                    <measurement group_id="O2" value="0.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.568"/>
                    <measurement group_id="O2" value="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Serious Adverse Events</title>
        <description>Number of participants with Serious Adverse Events (SAEs) probably, possibly or definitely related to the trial vaccine</description>
        <time_frame>within 26 weeks</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Serious Adverse Events</title>
          <description>Number of participants with Serious Adverse Events (SAEs) probably, possibly or definitely related to the trial vaccine</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Non-serious Adverse Events</title>
        <description>Number of participants with any, grade &gt;=3, and related non-serious unsolicited adverse events</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Non-serious Adverse Events</title>
          <description>Number of participants with any, grade &gt;=3, and related non-serious unsolicited adverse events</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event with intensity &gt;= Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event assessed as related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Grade &gt;= 3 Unsolicited Adverse Events</title>
        <description>Number of participants with Grade &gt;=3 Unsolicited Adverse Event probably, possibly, or definitely related to the study vaccine</description>
        <time_frame>within 29 days after vaccination</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Grade &gt;= 3 Unsolicited Adverse Events</title>
          <description>Number of participants with Grade &gt;=3 Unsolicited Adverse Event probably, possibly, or definitely related to the study vaccine</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local Adverse Events</title>
        <description>Number of participants with and intensity of solicited local AEs (pain, erythema, swelling, induration, and pruritis). Percentages based on subjects with a completed diary card.</description>
        <time_frame>within 8 days after vaccination</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Events</title>
          <description>Number of participants with and intensity of solicited local AEs (pain, erythema, swelling, induration, and pruritis). Percentages based on subjects with a completed diary card.</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited General Adverse Events</title>
        <description>Number of participants with solicited general AEs (body temperature increased, headache, myalgia, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with a completed diary card.</description>
        <time_frame>within 8 days after vaccination</time_frame>
        <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
            <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
            <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited General Adverse Events</title>
          <description>Number of participants with solicited general AEs (body temperature increased, headache, myalgia, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with a completed diary card.</description>
          <population>Full Analysis Set/ Booster Set i.e., all subjects having received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body temperature increased: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature increased: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature increased: Related Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Related Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Related Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Related Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Related Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <desc>AEs only collected for subjects that received a booster dose in POX-MVA-023. Subjects from Group 4 had a blood draw at Screening only, did not receive a booster dose and adverse events were not monitored/assessed for this group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose</title>
          <description>Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
        </group>
        <group group_id="E2">
          <title>Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose</title>
          <description>Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Lead, Clinical Operations</name_or_title>
      <organization>Bavarian Nordic A/S</organization>
      <phone>+45 3326 ext 8383</phone>
      <email>info@bavarian-nordic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

